Evidence map›Paper›PMID 33112553›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2020

Impact of Bone Marrow Natural Killer Cells (NK); Soluble TNF-α and IL-32 Levels in Myelodysplastic Syndrome Patients.

Salah Aref, Nada Khaled, Abdel Hady Al Gilany, Mohamed Ayed, Tarek Abouzeid, Doaa Attia

Open access · goldAbstract read
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Salah ArefHematology Unit, Clinical Pathology Department, Faculty of Medicine, Mansoura University, Egypt.ORCID 0000-0002-4822-5204
Nada KhaledHematology Unit, Clinical Pathology Department, Faculty of Medicine, Mansoura University, Egypt.
Abdel Hady Al GilanyPublic Health and Biostatistics Department, Mansoura University, Egypt.
Mohamed AyedHematology Unit, Clinical Pathology Department, Faculty of Medicine, Mansoura University, Egypt.
Tarek AbouzeidHematology Unit, Mansoura University Oncology Center, Mansoura University, Egypt.
Doaa AttiaHematology Unit, Clinical Pathology Department, Faculty of Medicine, Mansoura University, Egypt.
Mansoura University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMyelodysplastic syndromes (MDS) are complex clonal hemopoietic progenitor cell disorders that result from the evolution of aberrant clones which lead to leukemia. Disorders of the immune system serve important functions in the pathophysiology and progression of this disorder. This study aimed to assess the bone marrow natural killer cells percentage as well as soluble TNF-α and sIL-32 concentration levels in MDS patients.

methodsBone marrow samples were obtained from 34 MDS; 12 MDS-AML and 10 controls. The percentage of total NK cells and mature NK cells were determined by flowcytometry. Bone Marrow soluble TNF-α and sIL-32 concentration levels were measured by ELISA.

resultsThe percentage of total NK and mature NK cells were significantly lower in MDS patients as compared to controls (p.

Indexed as

Biomarkers, TumorBone MarrowCase-Control StudiesFemaleFollow-Up StudiesHumansInterleukinsKiller Cells, NaturalMaleMiddle AgedMyelodysplastic SyndromesPrognosisTumor Necrosis Factor-alphaBiomarkers, TumorIL32 protein, humanInterleukinsTumor Necrosis Factor-alphaAMLMDSNK cellssIL32sTNF-α

Identifiers

PMID33112553
PMCPMC7798173
OpenAlexW3097446235

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.